Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.
SCLC
ORR (Overall Response Rate), Percentage of subjects who reached complete remission (CR) and partial remission (PR), 6 months after the start of administration
SAE & SADR Incidence Rate, Serious Adverse Event \& Serious Adverse Drug Reaction Incidence Rate, 6 months after the start of administration
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.